Pular para o conteúdo principal
Ranking Invest

ALEC - Alector, Inc.

Segmento: HealthcareAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valuation estimado
-14,74%
-$ 492.69 Mi
Valor de Mercado
$ 238.95 Mi
Desconto (AV)-148.5%
IVR
-2.06A companhia vale -2,06 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-2.04O valuation alternativo equivale a -204% do valor de mercado da companhia.
MLL
-2.04O lucro líquido dos controladores em 16 trimestres equivale a -204% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

-$ 9.97 Mi

Dívida Líquida

-$ 50.07 Mi

L4T

-$ 117.85 Mi

MM4T

-1137.01%

Indicadores Básicos

ROE

1182.09%

Índices de Previsibilidade

Receita Líquida

F0.61

Lucro

C0.28

Margem

D0.56

Índices de Tendência

Receita Líquida

E-4.58

Lucro

C3.89

Margem

F-6.84

Índices de Endividamento

DIV/PAT

5.02

DIV/L4T

0.42

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.